- CEO
- Shao Hua Yang
- Full Time Employees
- 1,543
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Xinxiang China
- IPO Date
- Oct 27, 2021
- Business
- Tuoxin Pharmaceutical Group Co., Ltd. is a China-based biopharmaceutical company engaged in the research, development, manufacturing, and distribution of nucleoside and nucleotide active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and functional biochemical products. The company's product portfolio is organized into pyrimidine series, including cytosine, cytidine, 5-fluorocytosine (flucytosine), and 5-fluorocytidine; purine series, encompassing inosine, adenosine, acyclovir, and related derivatives; and nucleoside and nucleotide series, which feature citicoline sodium, ribavirin, uridine, cytarabine hydrochloride, and azvudine intermediates, primarily serving therapeutic applications across antiviral, antineoplastic, cardiovascular, and central nervous system indications. In addition to commercial API and intermediate supply, the company provides customized contract development and manufacturing organization (CDMO) and contract manufacturing (CMO) services, supported by proprietary technology platforms spanning efficient catalytic chemical synthesis, microbial fermentation, and semi-synthetic bioconversion. In recent operational and strategic developments, the company executed a corporate restructuring and rebranding, transitioning its corporate name from Xinxiang Tuoxin Pharmaceutical Co., Ltd. to Tuoxin Pharmaceutical Group Co., Ltd. To support capacity expansion and product diversification into non-nucleoside specialty APIs and functional health ingredients, the company established Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. and initiated construction of a major green biomanufacturing base in the Tuoketuo Economic Development Zone, while advancing commercialization initiatives in synthetic biology products such as ergothioneine. On the collaborative research front, its subsidiary Henan Nucleoside Drug Research Institute Co., Ltd. entered into strategic research partnerships with China Pharmaceutical University and Nanjing University of Chinese Medicine to develop vincamine formulations for pulmonary fibrosis, alongside formalizing joint industry-academia innovation agreements with Xinxiang University. Founded in 2005 and headquartered in Xinxiang, Henan Province, China, the company operates principal operating subsidiaries including Xinxiang Pharmaceutical Co., Ltd., Dingxin Pharmaceutical, Jingquan Biology, and Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd., marketing its products across domestic Chinese markets as well as international destinations in Asia, Europe, and other global regions under international Good Manufacturing Practice (GMP) standards and Drug Master File (DMF) regulatory filings.